Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
Beam Therapeutics (Nasdaq: BEAM), a biotechnology company focused on developing precision genetic medicines through base editing, has announced its participation in the 2024 Jefferies London Healthcare Conference. John Evans, CEO of Beam, will participate in a fireside chat on Tuesday, November 19, 2024, at 10:00 a.m. GMT in London. The presentation will be accessible via live webcast in the investor section of Beam's website and will remain archived for 60 days afterward.
Beam Therapeutics (Nasdaq: BEAM), un'azienda biotecnologica focalizzata nello sviluppo di medicine genetiche di precisione attraverso il base editing, ha annunciato la sua partecipazione alla 2024 Jefferies London Healthcare Conference. John Evans, CEO di Beam, prenderà parte a una chiacchierata informale martedì 19 novembre 2024, alle 10:00 ora GMT a Londra. La presentazione sarà accessibile tramite webcast in diretta nella sezione dedicata agli investitori del sito web di Beam e resterà archiviata per 60 giorni successivi.
Beam Therapeutics (Nasdaq: BEAM), una empresa de biotecnología centrada en el desarrollo de medicamentos genéticos de precisión a través de la edición base, ha anunciado su participación en la 2024 Jefferies London Healthcare Conference. John Evans, CEO de Beam, participará en una charla informal el martes 19 de noviembre de 2024, a las 10:00 a.m. GMT en Londres. La presentación estará disponible a través de una transmisión en vivo en la sección de inversores del sitio web de Beam y permanecerá archivada durante 60 días después.
Beam Therapeutics (Nasdaq: BEAM), 기초 편집을 통해 정밀 유전자 치료제를 개발하는 데 주력하는 생명공학 회사가 2024 Jefferies London Healthcare Conference에 참가한다고 발표했습니다. John Evans Beam CEO는 2024년 11월 19일 화요일 오전 10시 GMT에 런던에서 진행되는 화로 대화에 참석합니다. 발표는 Beam 웹사이트의 투자자 섹션에서 실시간 웹캐스트를 통해 접근 가능하며, 이후 60일 동안 아카이브됩니다.
Beam Therapeutics (Nasdaq: BEAM), une entreprise biotechnologique axée sur le développement de médicaments génétiques de précision par le biais de l'édition de bases, a annoncé sa participation à la 2024 Jefferies London Healthcare Conference. John Evans, PDG de Beam, participera à une discussion informelle le mardi 19 novembre 2024, à 10h00 GMT à Londres. La présentation sera accessible par webcast en direct dans la section investisseurs du site web de Beam et sera archivée pendant 60 jours par la suite.
Beam Therapeutics (Nasdaq: BEAM), ein Biotechnologieunternehmen, das sich auf die Entwicklung präziser genetischer Medikamente durch Basenedition konzentriert, hat seine Teilnahme an der 2024 Jefferies London Healthcare Conference angekündigt. John Evans, CEO von Beam, wird am Dienstag, den 19. November 2024, um 10:00 Uhr GMT in London an einem Fireside-Chat teilnehmen. Die Präsentation wird über einen Live-Webcast im Investorenbereich der Beam-Website zugänglich sein und wird für 60 Tage archiviert bleiben.
- None.
- None.
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:00 a.m. GMT in London.
A live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contact:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
FAQ
When is Beam Therapeutics (BEAM) presenting at the 2024 Jefferies London Healthcare Conference?
How can I watch Beam Therapeutics' (BEAM) presentation at the Jefferies Healthcare Conference?
How long will Beam Therapeutics' (BEAM) Jefferies Conference presentation be available online?
What type of presentation will Beam Therapeutics (BEAM) give at the 2024 Jefferies Conference?
